Answers are grounded in this paper and cite their sources.
Advanced breast cancer (BC) has a poor prognosis with limited effective treatment options, especially once the tumor develops resistance to standard therapies. The oncofetal antigen 5T4 is frequently overexpressed in BC cells, with limited expression in healthy adult tissues, making it an ideal target. XB010 is an antibody–drug conjugate (ADC) with a monomethyl auristatin E (MMAE) payload site specifically conjugated to a monoclonal antibody targeting 5T4 using a tandem-cleavage linker. Upon binding to 5T4 on the surface of tumor cells, XB010 is internalized, and the linker is enzymatically cleaved to release MMAE, which also has bystander activity in surrounding tumor cells.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: